Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00083252Phase 2Completed
A Phase 2 trial of talabostat in melanoma, sponsored by Point Therapeutics. Status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00083252.